Compounding: Groups Tell FDA To Drop “Traditional” and “Non-Traditional” Categories
Executive Summary
Stakeholders say it would create more confusion in the pharmacy and regulatory community; they also spar over whether volume, other criteria should be imposed to distinguish compounding types.
You may also be interested in...
Drug Shortages: FDA Says Market Must Reward Production Quality
FDA officials state in journal article that manufacturers are not incentivized to ensure quality and base competition entirely on price.
FDA Shortage Notification Mandate May Not Extend To Biologics
The agency has the option to issue regulations requiring biologics manufacturers to notify FDA of emerging production problems, but so far it’s only “something that we’re thinking about.”
Pfizer’s COVID-19 Vaccine Data In Young Children Could Place US FDA In Awkward Position Again
The agency is considering how to move forward as Pfizer studies a third shot after missing an efficacy endpoint in children age 2 to 5.